"Company","Current Parent Company","Parent at the Time of the Penalty Announcement","Recap of Ownership Changes","City / Town","County","Nation / Region","Company Number","Penalty (in pounds)","Penalty Year","Penalty Date","Offence Group","Offence Type","Violation Description","Settlement Type","Case Number","Agency","HQ Country of Parent","Ownership Structure of Parent","Major Industry of Parent","Specific Industry of Parent","Parent company ISIN","Source of Data","Source Notes" "HGCapital","Hg Capital","Hg Capital","","","","","","6,200,000","2021","20210729","competition-related offences","price-fixing or anti-competitive practices","The Competition and Markets Authority (CMA) found that from 2009 until 2017 the pharmaceutical company Advanz charged excessive and unfair prices for supplying liothyronine tablets which are used to treat thyroid hormone deficiency. The agency also fined two private equity firms, HGCapital and Cinven, that previously owned parts of the business.","","","Competition and Markets Authority","Germany","privately held","private equity (including portfolio companies)","private equity (including portfolio companies)","","https://www.gov.uk/government/news/cma-fines-pharma-firm-over-pricing-of-crucial-thyroid-drug","HGCapital’s fine was reduced to £6.2 million on appeal in 2023"